The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma

There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1. The 3-week cycle regimen was repeated until disease progression if it had no intolerable toxicity. The overall response rate was 61% (95%CI, 41-78%). The median overall survival and progression-free survival times were 14 months and 5.5 months, respectively. Of the already known risk factors of chemotherapy for advanced UC, only the performance status was a prognostic factor for OS. Overall, 16 of the 23 patients (70%) experienced grade 3/4 toxicities, and no fatal adverse events were observed. GCP therapy was a promising option as second-line or salvage therapy for advanced UC

Deformed Microcavity Quantum Cascade Lasers with Directional Emission

We report the experimental realization of deformed microcavity quantum cascade lasers (QCLs) with a Limaçon-shaped chaotic resonator. Directional light emission with a beam divergence of $\theta_{\|} \approx 33^{\circ}$ from QCLs emitting at λ ≈ 10µm was obtained in the plane of the cavity for deformations in the range 0.37 < ε < 0.43. An excellent agreement between measured and calculated far-field profiles was found. Both simulations and experiments show that the Limaçon-shaped microcavity preserves whispering gallery-like modes with high Q-factors for low deformations (ε < 0.50). In addition, while the measured spectra show a transition from whispering gallery-like modes to a more complex mode structure at higher pumping currents, we observed ‘universal far-field behavior’ for different intracavity mode distributions in the Limaçon microcavity, which can be explained by the distribution of unstable manifolds in ray optics simulations. Furthermore, the performance of the deformed microcavity lasers is robust with respect to variations of the deformation near its optimum value ε = 0.40, which implies that this structure reduces the requirements on photolithography fabrication. The successful realization of these microcavity lasers may lead to applications in optoelectronics.Engineering and Applied Science

High Performance Quantum Cascade Lasers Based on Three-Phononresonance Design

A quantum cascade laser structure based on three-phonon-resonance design is proposed and demonstrated. Devices, emitting at a wavelength of 9 μm, processed into buried ridge waveguide structures with a 3 mm long, 16 μm wide cavity and a high-reflection (HR) coating have shown peak output powers of 1.2 W, slope efficiencies of 1 W/A, threshold current densities of 1.1 kA/cm2, and high wall-plug efficiency of 6% at 300 K. A 3 mm long, 12 μm wide buried-heterostructure device without a HR coating exhibited continuous wave output power of as high as 65 mW from a single facet at 300 K.Engineering and Applied Science

Semiconductor Lasers With Integrated Plasmonic Polarizers

The authors reported the plasmonic control of semiconductor laser polarization by means of metallic gratings and subwavelength apertures patterned on the laser emission facet. An integrated plasmonic polarizer can project the polarization of a semiconductor laser onto other directions. By designing a facet with two orthogonal grating-aperture structures, a polarization state consisting of a superposition of a linearly and right-circularly polarized light was demonstrated in a quantum cascade laser; a first step toward a circularly polarized laser.Engineering and Applied Science

Ancient Sources of the Perennial Philosophy

Articledepartmental bulletin pape

Iodine-125 Seed Implantation (Permanent Brachytherapy) for Clinically Localized Prostate Cancer

From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treated using iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment’s effi cacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classifi ed as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of diffi culty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the fi rst month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and eff ective for localized prostate cancer within short-term follow up.</p